UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
|
||||
Washington, D.C. 20549
|
||||
FORM 8-K
|
||||
CURRENT REPORT
|
||||
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
|
||||
August 10, 2012
Date of Report (Date of earliest event reported)
|
||||
HESKA CORPORATION
(Exact name of Registrant as specified in its charter)
|
||||
Delaware
|
000-22427
|
77-0192527
|
||
(State or other jurisdiction of
incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
||
3760 Rocky Mountain Avenue
Loveland, Colorado 80538
(Address of principal executive offices, including zip code)
|
||||
(970) 493-7272
(Registrant’s telephone number, including area code)
|
||||
Not Applicable
(Former name or former address, if changed since last report)
|
||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
|
||||
[ ] Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
||||
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
||||
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
||||
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
||||
|
HESKA CORPORATION
a Delaware corporation
|
|
|
|
Dated: August 10, 2012
|
By: /s/ Jason A. Napolitano
Jason A. Napolitano
Executive Vice President, Chief Financial Officer
and Secretary
|
Exhibit Number
|
Description
|
99.1
|
Press Release dated August 10, 2012
|
At Heska Corporation:
|
At Hayden IR:
|
Jason Napolitano, Executive Vice President & CFO
|
Brett Maas, Managing Partner
|
(970) 493-7272, Ext. 4105
|
(646) 536-7331
|
brett@haydenir.com
|
•
|
Consolidated revenue was $18.3 million, an increase of 5% compared to the $17.4 million in the second quarter of 2011.
|
•
|
Core Companion Animal Health revenue of $15.7 million, a 12% increase as compared to $14.0 million for the second quarter of 2011.
|
•
|
Gross profit of $8.0 million, or 44.0% gross margin, compared to gross profit of $7.5 million, or a 42.8% gross margin, for the second quarter of 2011.
|
•
|
$383 thousand in operating income, as compared to $887 thousand in operating income in the second quarter of 2011.
|
•
|
Heska completed the quarter with $7.6 million in cash with no debt and $19.2 million in working capital.
|
Three Months Ended
June 30,
|
Six Months Ended
June 30,
|
|||||||||||||||
2011 | 2012 |
2011
|
2012
|
|||||||||||||
Revenue, net:
|
||||||||||||||||
Core companion animal health
|
$ | 14,023 | $ | 15,701 |
$
|
30,464 |
$
|
32,281 | ||||||||
Other vaccines, pharmaceuticals and products
|
3,424 | 2,570 | 6,488 | 5,165 | ||||||||||||
Total revenue, net
|
17,447 | 18,271 | 36,952 | 37,446 | ||||||||||||
Cost of revenue
|
9,978 | 10,223 | 21,185 | 20,475 | ||||||||||||
Gross profit
|
7,469 | 8,048 | 15,767 | 16,971 | ||||||||||||
Operating expenses:
|
||||||||||||||||
Selling and marketing
|
3,570
|
4,751 | 7,530 | 9,639 | ||||||||||||
Research and development
|
703 | 203 | 1,034 | 537 | ||||||||||||
General and administrative
|
2,309
|
2,711 | 4,776 | 5,330 | ||||||||||||
Total operating expenses
|
6,582
|
7,665 | 13,340 | 15,506 | ||||||||||||
Operating income
|
887
|
|
383 | 2,427 |
|
1,465 | ||||||||||
Interest and other (income) expense, net
|
142
|
(57 | ) | 165 | 85 | |||||||||||
Income before income taxes
|
745
|
|
440 | 2,262 |
|
1,380 | ||||||||||
Income tax expense:
|
|
|
||||||||||||||
Current tax expense | 53 | 34 | 159 | 82 | ||||||||||||
Deferred tax expense | 235 | 144 | 730 | 452 | ||||||||||||
Total income tax expense | 288 | 178 | 889 | 534 | ||||||||||||
Net income
|
$
|
457
|
|
$
|
262
|
$
|
1,373 |
|
$
|
846 | ||||||
Basic net income per share
|
$ | 0.09 |
|
$ | 0.05 |
$
|
0.26
|
|
$
|
0.16 | ||||||
Diluted net income per share
|
$ | 0.09 |
|
$ | 0.05 |
$
|
0.26 |
|
$
|
0.15 | ||||||
Shares used for basic net income per share
|
5,234 | 5,327 | 5,233 | 5,296 | ||||||||||||
Shares used for diluted net income per share
|
5,353 | 5,583 | 5,298 | 5,517 |
December 31,
2011
|
June 30,
2012
|
||||||
Cash and cash equivalents
|
$
|
6,332
|
$
|
7,624 | |||
Total current assets
|
28,891
|
29,728 | |||||
Property and equipment, net | 4,869 | 5,188 | |||||
Total assets
|
61,894
|
63,186 | |||||
Dividends payable
|
--
|
534 | |||||
Total current liabilities
|
9,289
|
10,517 | |||||
Stockholders' equity
|
48,439
|
48,764 |